Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study

Simona Sciara, Roberto Castelli, Giorgio Lambertenghi Deliliers, Giuseppe Pantaleo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

Anaemia is a complication reported in up to 70% of the multiple myeloma patients (MM), with remarkable clinical, cognitive and socio-relational consequences. Anaemia relates to the course of MM, normalizing in patients during remission and reappearing in relapsing/non-responding patients. In a pilot study with 31 patients with MM and transfusion-dependent anaemia, we evaluated the effects of Binocrit (biosimilar epoetin alfa) on transfusions, haemoglobin levels, mental status (mini-mental state evaluation) and the patients’ social-relational functioning and quality of life (QoL). Within a 12-week interval, patients received 40.000 U Binocrit once a week. Binocrit significantly decreased the incidence of transfusion, regardless of the patients’ transfusion history, and significantly increased haemoglobin levels (before-and-after-treatment median haemoglobin values = 8.20 vs. 9.40 g/dl, respectively; Wilcoxon Z test, p < .001). A comparatively greater increment in haemoglobin levels among patients who responded to first vs. additional lines of chemotherapy was also observed. Importantly, we additionally found moderate-to-strong positive associations between increments in haemoglobin levels and corresponding increments both in psychological well-being and QoL (FACT-An scores) and the patients’ cognitive status (mini-mental state evaluation scores). After statistically controlling for possible concurrent benefits of anti-myeloma therapy, increments in haemoglobin levels clearly predicted both increments in socio-relational FACT-An scores (Spearman’s rho = 0.60, p < .001) and in cognitive functioning scores (Spearman’s rho = 0.49, p < .006). Binocrit thus appears as an effective, well-tolerated agent for the management of myeloma anaemia, whose documented benefits include amelioration of anaemia, reduction in transfusion, and improvements in the patients’ social-relational functioning and cognitive well-being.
Lingua originaleEnglish
pagine (da-a)779-786
Numero di pagine8
RivistaAnnals of Hematology
Volume96
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Aged
  • Aged, 80 and over
  • Anaemia
  • Anemia
  • Biosimilar Pharmaceuticals
  • Biosimilar epoetin α (Binocrit)
  • Blood Transfusion
  • Cognition
  • Cognitive functioning and psychosocial quality of life (QoL)
  • Epoetin Alfa
  • Erythroid-stimulating agents (ESAs)
  • Female
  • Hematology
  • Hemoglobins
  • Humans
  • Male
  • Multiple Myeloma
  • Multiple myeloma
  • Pilot Projects
  • Quality of Life
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study'. Insieme formano una fingerprint unica.

Cita questo